glp-1 drugs pharmaceutical companies partnerships 2025 Shortage = Over GLP-1s in 2025: Who's Using
Description
Others are taking a more middle-of-the-road approach by not eliminating coverage outright, but rather tightening restrictions
Innovator Novo Nordisk launched its semaglutide brands Wegovy and Ozempic in India last year, racing to capture early market share before losing patent exclusivity on 20 March 2026
Broader lifestyledriven risk factors, rising obesity rates, and earlier onset of metabolic disorders are intensifying the pressure on the healthcare system to expand access to effective antidiabetic medicines
M.DeCensiA.SahasrabuddheV
